1. Home
  2. FEED vs DRMA Comparison

FEED vs DRMA Comparison

Compare FEED & DRMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

FEED

ENvue Medical Inc. Common Stock

N/A

Current Price

$0.66

Market Cap

5.6M

Sector

N/A

ML Signal

N/A

Logo Dermata Therapeutics Inc.

DRMA

Dermata Therapeutics Inc.

HOLD

Current Price

$1.23

Market Cap

5.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FEED
DRMA
Founded
2003
2014
Country
United States
United States
Employees
14
9
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.6M
5.1M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
FEED
DRMA
Price
$0.66
$1.23
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$10.00
AVG Volume (30 Days)
595.7K
54.9K
Earning Date
04-15-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$650.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.63
$0.59
52 Week High
$6.09
$7.33

Technical Indicators

Market Signals
Indicator
FEED
DRMA
Relative Strength Index (RSI) 27.04 44.49
Support Level N/A $1.13
Resistance Level $0.97 $1.40
Average True Range (ATR) 0.09 0.08
MACD 0.00 -0.00
Stochastic Oscillator 5.94 0.00

Price Performance

Historical Comparison
FEED
DRMA

About FEED ENvue Medical Inc. Common Stock

ENvue Medical Inc develops medical devices for enhanced navigation in clinical procedures. The company provides personalized navigation technology to assist clinicians in placing feeding tubes safely and efficiently. Its ENvue system uses smart feeding tubes with sensors, body mapping, and continuous visual guidance to confirm accurate positioning and reduce complications like lung misplacement. The company conducted the business through two primary operating segments: NanoVibronix and ENvue. The firm generates the majority of its revenue from NanoVibronix, which derives revenues from selling its products directly to patients as well as through distributor agreements. ENvue derives revenues from selling its Systems and Nasoenteral tubes.

About DRMA Dermata Therapeutics Inc.

Dermata Therapeutics Inc develops and commercializes dermatology products for the treatment of common skin conditions. It focuses on leveraging prior clinical and technical expertise to develop OTC treatments for conditions such as acne, psoriasis, rosacea, and seborrheic dermatitis. The company is currently developing a once-weekly acne treatment system that utilizes an active ingredient from the OTC monograph in combination with the company's Spongilla technology. It intends to apply its Spongilla technology platform across a range of dermatologic and aesthetic skin applications, including intradermal delivery of botulinum toxin. The company's operates in one segment, which is the business of developing, branding, marketing, and commercializing direct to consumer skincare products.

Share on Social Networks: